News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Apr 23, 2012
London, UK; Tokyo, Japan; April 23 2012: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd.
Apr 16, 2012
Porton Down, UK; 16 April 2012: GW Pharmaceuticals plc (AIM: GWP) confirms that it has now earned the €11.9 million milestone payment due as a result of the recently amended terms of its licence agr
Mar 15, 2012
Financial terms amended to provide for near term €12m (£10m) milestone payment to GW
Mar 08, 2012
Porton Down, UK; 8 March 2012: GW Pharmaceuticals plc (AIM: GWP) today announces that, effective March 1st 2012, Professor Vincenzo Di Marzo has agreed to direct GW’s global pre-clinical research pr
Feb 07, 2012
Porton Down, UK; 7 February 2012: GW Pharmaceuticals plc (AIM: GWP) today announces a regulatory update for Sativex® (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) oromucosal spray.

Pages